

P35

## An aqueous extract of *Platycodi radix* inhibits LPS-induced NF- $\kappa$ B nuclear translocation in A549 cells

Byung-Tae Choi, Jun-Hyuk Lee, Young-Hyun Choi<sup>1</sup>,  
Ho-Sung Kang<sup>2</sup> and Un Bock Jo<sup>3</sup>

Dept. of Anatomy and <sup>1</sup>Biochemistry, College of Oriental Medicine, Research Institute of Oriental Medicine, Dong-Eui University, Busan 614-052  
<sup>2</sup>Dept. of Molecular Biology, College of Natural Sciences, <sup>3</sup>Dept. of Biology Education, College of Education, Pusan National University, Busan 609-735

We investigated the effects of aqueous extract from *Platycodi radix* (AEPR), a traditional drug used to treat acute lung inflammatory disease, on lipopolysaccharide (LPS)-induced inflammation in A549 human cultured airway epithelial cells. Nuclear factor- $\kappa$  B (NF- $\kappa$  B) and its inhibitory regulator, inhibitory- $\kappa$  B (I- $\kappa$  B), play crucial roles in LPS-induced inflammatory response. We show that LPS-induced nuclear translocation of NF- $\kappa$  Bp65 is inhibited by AEPR. LPS-induced expression of I- $\kappa$  B  $\alpha$ , which is expressed by LPS-induced activation of NF- $\kappa$  B, is inhibited by AEPR as well. Beside LPS-induced expression of a group of genes, such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), are repressed by AEPR. We also found that expression of heat shock protein 70 (Hsp70), which has an anti-inflammatory activity, is increased by AEPR plus LPS. These results suggest that AEPR may act as a therapeutic agent for inflammatory disease through regulating the activity of NF- $\kappa$  B and expression of inflammatory genes.